Sanofi-Pasteur's pandemic flu vaccine tested in US pregnant women
This article was originally published in Scrip
Sanofi-Pasteur's candidate influenza H1N1 vaccine has started to be tested in pregnant women through the NIAID-funded national network of vaccine and treatment evaluation units in the US. Results are expected in mid to late October. Similar studies with candidate H1N1 vaccines from other manufacturers are planned by the NIAID in pregnant women.
You may also be interested in...
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.